Prevalence of Precancerous Lesions Based on Digital Cervicography with VIA/VILI among Women Positive for High-Risk Human Papillomavirus Serotypes: A Screening Center-Based Study in Cameroon  

作　　者：Jeffrey-Lewis Nzang Cliford Ebontane Ebong Simon Manga Florence Manjuh Félix Essiben Isidore Tompeen Judith Seungue Serge Robert Nyada Jeanne Hortence Fouedjio Ymele Fouelifack Julius Sama Dohbit Jeffrey-Lewis Nzang;Cliford Ebontane Ebong;Simon Manga;Florence Manjuh;Félix Essiben;Isidore Tompeen;Judith Seungue;Serge Robert Nyada;Jeanne Hortence Fouedjio;Ymele Fouelifack;Julius Sama Dohbit(Kloukanmey Zonal Hospital, Mdecins Sans Frontires, Kloukanmey, Benin;Faculty of Medicine and Biomedical Sciences, University of Yaound 1, Yaound, Cameroon;Gynecology and Obstetrics Unit, Central Hospital of Yaound, Yaound, Cameroon;Womens Health Program, Cameroon Baptist Convention Health Services, Yaound, Cameroon;Department of Obstetrics and Gynaecology, Gyneco-Obstetric and Pediatric Hospital of Yaound, Yaound, Cameroon;Expanded Program of Immunization, Ministry of Health, Yaound, Cameroon;Department of Obstetrics and Gynaecology, Gynaecological Endoscopic Surgery and Human Reproductive Teaching Hospital, Yaounde, Cameroon;Department of Obstetrics and Gynaecology, University of Dschang, Dschang, Cameroon;Higher Institute of Medical Technology Nkolondom, Yaound, Cameroon)

机构地区：[1]Kloukanmey Zonal Hospital, Mdecins Sans Frontires, Kloukanmey, Benin [2]Faculty of Medicine and Biomedical Sciences, University of Yaound 1, Yaound, Cameroon [3]Gynecology and Obstetrics Unit, Central Hospital of Yaound, Yaound, Cameroon [4]Womens Health Program, Cameroon Baptist Convention Health Services, Yaound, Cameroon [5]Department of Obstetrics and Gynaecology, Gyneco-Obstetric and Pediatric Hospital of Yaound, Yaound, Cameroon [6]Expanded Program of Immunization, Ministry of Health, Yaound, Cameroon [7]Department of Obstetrics and Gynaecology, Gynaecological Endoscopic Surgery and Human Reproductive Teaching Hospital, Yaounde, Cameroon [8]Department of Obstetrics and Gynaecology, University of Dschang, Dschang, Cameroon [9]Higher Institute of Medical Technology Nkolondom, Yaound, Cameroon

出　　处：《Open Journal of Obstetrics and Gynecology》2024年第6期967-978,共12页妇产科期刊（英文）

摘　　要：Background: Since 2021, high-risk Human Papilloma Virus (HR-HPV) testing has been the recommended screening test for cervical cancer for all settings;either used alone in a “test and treat” strategy, or with a triage test, with or without biopsy, before treatment. Cameroon has rolled out immunization against HPV 16 and 18, but studies show a higher prevalence of non-16/18 HR-HPV types. Objectives: Determine the prevalence of precancerous lesions, in women with HR-HPV infection and evaluate association of digital cervicography (DC) VIA/VILI positivity with HPV serotype, as a measure of their contribution to precancer and cancer incidence. Methodology: The study was cross-sectional, descriptive, and analytic. It took place at the Etoug-Ebe and Ekoudoum Baptist Hospitals in Yaoundé, during the period April-September 2022. We reviewed the records of women screened for cervical cancer between February 2020 and December 2021 and evaluated the prevalence of lesions on digital cervicography (DC) with VIA/VILI for women positive for HR-HPV serotypes. The data were analyzed using SPSS version 20.0 for Windows. P values Results: We identified 315 cases with a positive HR-HPV deoxyribonucleic acid (DNA) test, 224 (71.1%) had a DC VIA/VILI triage test done. Of these, 30 (13.4%) women had a positive DC VIA/VILI, with five women (2.2%) having lesions suggestive of cancer. Out of 11 cases positive for HPV 16 alone, 05 (45.5%) had a positive DC VIA/VILI test. Of the 14 cases positive for HPV 18 alone, 03 (21.4%) had a positive VIA/VILI, meanwhile only 19 (10.7%) of the 177 cases positive for non-16/18 HPV had a positive VIA/VILI test. Conclusion: A high proportion of women (13.4%) with HR HPV had a positive DC VIA/VILI, with a significant proportion (2.2%) having lesions suggestive of invasive cervical cancer HR-HPV serotype was associated with DC VIA/VILI positivity;HPV 16 had the strongest association (45.5%), followed by HPV 18 (21.4%), and non-16/18 HR-HPV (10.7%), suggesting a decreasing order of oncogenicity.Background: Since 2021, high-risk Human Papilloma Virus (HR-HPV) testing has been the recommended screening test for cervical cancer for all settings;either used alone in a “test and treat” strategy, or with a triage test, with or without biopsy, before treatment. Cameroon has rolled out immunization against HPV 16 and 18, but studies show a higher prevalence of non-16/18 HR-HPV types. Objectives: Determine the prevalence of precancerous lesions, in women with HR-HPV infection and evaluate association of digital cervicography (DC) VIA/VILI positivity with HPV serotype, as a measure of their contribution to precancer and cancer incidence. Methodology: The study was cross-sectional, descriptive, and analytic. It took place at the Etoug-Ebe and Ekoudoum Baptist Hospitals in Yaoundé, during the period April-September 2022. We reviewed the records of women screened for cervical cancer between February 2020 and December 2021 and evaluated the prevalence of lesions on digital cervicography (DC) with VIA/VILI for women positive for HR-HPV serotypes. The data were analyzed using SPSS version 20.0 for Windows. P values Results: We identified 315 cases with a positive HR-HPV deoxyribonucleic acid (DNA) test, 224 (71.1%) had a DC VIA/VILI triage test done. Of these, 30 (13.4%) women had a positive DC VIA/VILI, with five women (2.2%) having lesions suggestive of cancer. Out of 11 cases positive for HPV 16 alone, 05 (45.5%) had a positive DC VIA/VILI test. Of the 14 cases positive for HPV 18 alone, 03 (21.4%) had a positive VIA/VILI, meanwhile only 19 (10.7%) of the 177 cases positive for non-16/18 HPV had a positive VIA/VILI test. Conclusion: A high proportion of women (13.4%) with HR HPV had a positive DC VIA/VILI, with a significant proportion (2.2%) having lesions suggestive of invasive cervical cancer HR-HPV serotype was associated with DC VIA/VILI positivity;HPV 16 had the strongest association (45.5%), followed by HPV 18 (21.4%), and non-16/18 HR-HPV (10.7%), suggesting a decreasing order of oncogenicity.

关 键 词：HIGH-RISK Human Papillomavirus PRECANCEROUS Digital Cervicography VIA/VILI SEROTYPE 

分 类 号：R73[医药卫生—肿瘤]